Since the current study showed that TQ significantly inhibited NLRP3 in BC, it would be beneficial to investigate the impact of TQ/cyclin D on CDK4/6 in combination with Abemaciclib® in BC, as it might provide a synergistic effect. Here, CDK4 is linked to breast cancer.